MedTrace Logo

Metformin Plus Insulin on Non-obese Autoimmune Diabetes

NCT03513874 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-03-18

No results posted yet for this study

Summary

The objective of this study is to evaluate the therapeutic effect of metformin as additional treatment with insulin on non-obese autoimmune diabetes.

Conditions

  • Type 1 Diabetes Mellitus
  • Autoimmune Diabetes

Interventions

DRUG

Metformin

Patients will be subscribed with 850mg metformin orally twice daily. Insulin will be continued as routine therapy.

DRUG

Insulin

Patients will continue insulin therapy following physicians' instructions.

Sponsors & Collaborators

  • Second Xiangya Hospital of Central South University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2020-12-31
Completion
2021-04-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03513874 on ClinicalTrials.gov